ABCs of Radioisotopes Used for Radioimmunotherapy: α- and β-Emitters

References

• McLaughlin, P., Grillo-Lopez, A.J., Link, BK., Levy, R., Czucz-man, M.S., Williams, M.E., et al. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lympho-ma: Half of patients respond to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825–2833.
   PubMed Web of Science ®Google Scholar
• Piro, L.D., White, CA., Grillo-López, A.J., Janakiraman, N., Saven, A., Beck, TM., et al. (1999) "Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma", Annals of Oncology, 10, 655–661.
   PubMed Web of Science ®Google Scholar
• Hainsworth, J.D., Burris, H.A. 3rd, Morrissey, L.H., Litchy, S., Scullin, D.C. Jr, Bearden, J.D. 3rd, et al. (2000) "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma", Blood, 95, 3052 — 3056.
   PubMedGoogle Scholar
• Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., et al. (2001) "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation", Blood, 97, 101 — 106.
   Google Scholar
• Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Klippenstein, D., Loud, P., et al. (2001) "Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report", Blood, 98, 601a [abstract 2518].
   Google Scholar
• Czuczman, M.S., Grillo-López, A.J., White, CA., Saleh, M., Gordon, L., LoBuglio, A.F., et al. (1999) "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy", Journal of Clinical Oncology, 17, 268 —276.
   PubMedGoogle Scholar
• Press, 0.W., Corcoran, M., Subbiah, K., Hamlin, D.K., Wilbur, D.S., Johnson, T., et al. (2001) "A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts", Blood, 98, 2535–2543.
   PubMed Web of Science ®Google Scholar
• Dillman, R.O. (2002) "Radiolabeled anti-CD20 monoclonal anti-bodies for the treatment of B-cell lymphoma", Journal of Clinical Oncology, 20, 3545 — 3557.
   PubMedGoogle Scholar
• Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emma-nouilides, C., Raubitschek, A., et al. (1999) "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20( +) B-cell non-Hodgkin's lymphoma", Journal of Clinical Oncology, 17, 3793–3803.
   PubMed Web of Science ®Google Scholar
• Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) "Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritux-imab-refractory follicular non-Hodgkin's lymphoma", Journal of Clinical Oncology, 20, 3262–3269.
   Google Scholar
• Wiseman, G.A., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S., Bartlett, N.L., et al. (2002) "Ibritumomab tiuxetan radioimmu-notherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II muticenter trial", Blood, 99, 4336–3442.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Zelenetz, AD., Press, 0.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of Bmcar (iodine I 131 tositumomab) for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas", Journal of Clinical Oncology, 19, 3918–3928.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Estes, J., Zasadny, KR., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259–1266.
   Google Scholar
• Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, AZ., Knox, S.J., Radford, J.A., et al. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", Journal of Clinical Oncology, 18, 1316–1323.
   PubMed Web of Science ®Google Scholar
• Horning, S.J., Lucas, J.B., Younes, A., Podoloff, D., Jain, V., Kroll, S., et al. (2000) "Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multicenter phase II study", Blood, 96, 508a [abstract 2184].
   Google Scholar
• Kaminski, M.S., Gribben, T., Estes, J., Ross, C.W., Regan, D., Zasadnyk, K., et al. (1998) "1-131 anti-B! antibody for previously untreated follicular lymphoma (FL): clinical and molecular remis-sions", Proceedings of the American Society for Clinical Oncology, 17, 2a [abstract].
   Google Scholar
• Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90—labeled ibritumomab tiuxetan radioimmu-notherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma", Journal of Clinical Oncology, 20, 2453–2463.
   PubMed Web of Science ®Google Scholar
• Davis, T.A., Kaminski, M.S., Leonard, J.P., Gregory, S.A., Wahl, R., Hsu, F.Y., et al. (2001) "Results of a randomized trial of Bexxar (tositumomab and iodine I 131 tositumomab) vs. unlabeled tositumomab in patients with relapse or refractory low-grade or transformed non-Hodgkin's lymphoma", Blood, 98, 843a [abstract 3503].
   Google Scholar
• Cheson, B.D. (2002) "Hematologic malignancies: new developments and future treatments", Seminars in Oncology, 29\(Suppl. 13), 33–45.
   PubMed Web of Science ®Google Scholar
• Strauchen, J.A. (1989) "Interleukin receptors in lymphoid lesions: relevance to diagnosis, biology, and therapy", Pathology Annual, 24, 149–165.
   Google Scholar
• Morris, J.C. and Waldmann, T.A. (2000) "Advances in interleukin 2 receptor targeted treatment", Annals of Rheumatic Diseases, 59(Suppl. I), i109 —i114.
   Google Scholar
• Uchiyama, T., Hori, T., Tsudo, M., Wano, Y., Umadome, H., Tamori, S., et al. (1985) "Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells", Journal of Clinical Investigation, 76, 446–453.
   PubMed Web of Science ®Google Scholar
• Uchiyama, T., Broder, S. and Waldmann, T.A. (1981) "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac(+ ) cells", Journal of Immunology, 126, 1292–1397.
   Google Scholar
• Waldmann, T.A., Greene, W.C., Sarin, P.S., Saxinger, C., Blayney, D.W., Blattner, W.A., et al. (1984) "Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac: monoclonal antibody identifying the human receptor for T cell growth factor", Journal of Clinical Investigation, 73, 1711–1718.
   Google Scholar
• Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K. and Uchino, H. (1977) "Adult T-cell leukemia: clinical and hematologic features of 16 cases", Blood, 80, 481–492.
   Google Scholar
• Reitz, M.S. Jr, Poiesz, B.J., Ruscetti, F.W. and Gallo, R.C. (1981) "Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes", Proceedings of the National Academy of Sciences of the United States of America, 78, 1887–1891.
   Web of Science ®Google Scholar
• Madeleine, M.M., Wiktor, S.Z., Goedert, ii., Manns, A., Levine, P.H., Biggar, R.J., et al. (1993) "HTLV-I and HTLV-II world-wide distribution: reanalysis of 4,832 immunoblot results", International Journal of Cancer, 54, 255–260.
   PubMed Web of Science ®Google Scholar
• Shimoyama, M. (1991) "Diagnosis criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group (1984-87)", British Journal of Haematology, 7, 428–437.
   Google Scholar
• Waldmann, T.A., White, J.D., Carrasquillo, J.A., Reynolds, J.C., Paik, C.H., Gansow, 0.A., et al. (1995) "Radioimmunotherapy of interleukin-2R-expressing adult T-cell leukemia with yttrium-90 — labeled anti-Tac", Blood, 86, 4063–4075.
   PubMed Web of Science ®Google Scholar
• Phillips, K.E., Herring, B., Wilson, L.A., Rickford, M.S., Zhang, M., Goldman, C.K., et al. (2000) "IL-2R-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ra interaction", Cancer Research, 60, 6977–6984.
   PubMed Web of Science ®Google Scholar
• Cassidy, J., Newell, D.R. and Wedge, S.R. (1993) "Pharmacolci-netics of high molecular weight agents", Cancer Surveys, 17, 315 — 341.
   Google Scholar
• Knox, Si. (1995) "Overview of studies on experimental radio-immunotherapy", Cancer Research, 55, 5832s— 5835s.
   Google Scholar
• Axworthy, D.B., Reno, J.M., Hylarides, M.D., Mallett, R.W., Theodore, L.J., Gustayson, L.M., et al. (2000) "Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity", Proceedings of the National Academy of Sciences of the United States of America, 6, 406–414.
   PubMed Web of Science ®Google Scholar
• Yao, Z., Zhang, M., Axworthy, D.B., Garmestani, K., Park, L., Park, C.W., et al. (2002) "Radioimmunotherapy of A431 xeno-grafted mice with pretargeted B3 antibody-streptavidin and 90Y- labeled1,4,7,10-tetra-azacyclododecane-N,N',/V",Ar-tetra-aceticacid (DOTA)-biotin", Cancer Research, 62, 5755–5760.
   Google Scholar
• Zhang, M., Yao, Z., Garmestani, K., Axworthy, D.B., Zhang, Z., Mallett, R.W., et al. (2002) "Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the a-emitting radio-nuclide", Blood, 100, 208–216.
   Google Scholar
• Goshorn, S., Sanderson, J., Axworthy, D., Lin, Y., Hylarides, M. and Schultz, J. (2001) "Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy", Cancer Biotherapy and Radiopharmacology, 16, 109 — 123.
   PubMed Web of Science ®Google Scholar
• Weiden, P.L., Breitz, H.B., Press, 0., Appelbaum, J.W., Bryan, J.K., Gaffigan, S., et al. (2000) "Pretargeted radioimmunotherapy (PRITTm) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results", Cancer Biotherapy and Radio-pharmacology, 15, 15–29.
   PubMed Web of Science ®Google Scholar
• Fritzberg, AR. (1998) "Antibody pretargeted radiotherapy: a new approach and a second chance", Journal of Nuclear Medicine, 39, 20N — 22N.
   Google Scholar
• Kaminski, M.S., Zasadny, KR., Francis, I.R., Milik, A.W., Ross, C.W., Moon, S.D., et al. (1993) "Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody", New England Journal of Medicine, 329, 459–465.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D. (2003) "Radioimmunotherapy of non-Hodgkin lymphomas", Blood, 101, 391 —398.
   Google Scholar
• Press, 0.W., Shan, D., Howell-Clark, J., Eary, J., Appelbaum, FR., Matthews, D., et al. (1996) "Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells", Cancer Research, 56, 2123–2129.
   PubMed Web of Science ®Google Scholar
• Humm, J.L. and Chin, L.N. (1993) "A model of cell inactivation by alpha-particle internal emitters", Radiation Research, 134, 143–150.
   Google Scholar
• Nikula, T.K., McDevitt, MR., Finn, RD., Wu, C., Kozak, R.W., Garmestani, K., et al. (1999) "Alpha-emitting bismuth cyclohex-ylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry", Journal of Nuclear Medicine, 40, 166–176.
   PubMed Web of Science ®Google Scholar
• McDevitt, MR., Ma, D., Lai, L.T., Simon, J., Borchardt, P., Frank, R.K., et al. (2001) "Tumor therapy with targeted atomic nanogenerators", Science, 294, 1537–1540.
   Google Scholar
• Macklis, R.M., Kinsey, B.M., Kassis, AT., Ferrara, J.L., Atcher, R.W., Hines, J.J., et al. (1988) "Radioimmunotherapy with alpha-particle-emitting immunoconjugates", Science, 240, 1024–1026.
   Google Scholar
• McDevitt, MR., Sgouros, G., Finn, RD., Humm, J.L., Jurcic, J.G., Larson, S.M. et al. (1998) "Radioimmunotherapy with alpha-emitting nuclides", European Journal of Nuclear Medicine, 25, 1341 —1351.
   PubMed Web of Science ®Google Scholar
• Hartmann, F., Horak, EM., Garmestani, K., Wu, C., Brechbiel, MW., Kozak, R.W., et al. (1994) "Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac", Cancer Research, 54, 4362–4370.
   PubMed Web of Science ®Google Scholar
• Horak, E., Hartmann, F., Garmestani, K., Wu, C., Brechbiel, M., Gansow, 0.A., et al. (1997) "Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead 212-DOTA-AE1", Journal of Nuclear Medicine, 38, 1944–1950.
   PubMed Web of Science ®Google Scholar
• Zhang, M., Zhang, Z., Garmestani, K., Schultz, J., Axworthy, D.B., Goldman, C.K., et al. (2003) "Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts", Proceedings of the National Academy of Sciences of the United States of America, 100, 1891 — 1895.
   Web of Science ®Google Scholar